---
title: "U.S. stock market update: Incannex Healthcare down 10.93%"
description: "Incannex Healthcare fell 10.93%; Eli Lilly fell 1.33%, with a trading volume of USD 882 million; Pfizer fell 0.56%, with a trading volume of USD 534 million; Merck fell 0.54%, with a trading volume of"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258751138.md"
published_at: "2025-09-24T18:23:03.000Z"
---

# U.S. stock market update: Incannex Healthcare down 10.93%

> Incannex Healthcare fell 10.93%; Eli Lilly fell 1.33%, with a trading volume of USD 882 million; Pfizer fell 0.56%, with a trading volume of USD 534 million; Merck fell 0.54%, with a trading volume of USD 490 million; Johnson & Johnson rose 0.02%, with a market capitalization of USD 425.3 billion

**U.S. Stock Market Midday Update**

**Stocks with High Trading Volume in the Industry**

Eli Lilly fell 1.33%, with increased trading volume. Based on recent important news:

1.  On September 24, Eli Lilly announced a $6.5 billion investment to build a factory in Houston, Texas, to enhance the production capacity of small molecule drugs, particularly the experimental oral weight loss drug orforglipron. This move aims to address the surge in demand for weight loss drugs in the U.S. and reduce supply chain risks associated with policy uncertainties. Following the announcement, the market held an optimistic view on the company's future development, but short-term stock price volatility increased.
    
2.  On September 23, South Korean biopharmaceutical company Celltrion announced the acquisition of Eli Lilly's biopharmaceutical manufacturing facility in New Jersey for $330 million. This move is seen as a strategic step for Celltrion to enhance its manufacturing capabilities in the U.S., which may exert some pressure on Eli Lilly's short-term stock price.
    
3.  On September 23, options trading by financial giants on Eli Lilly's stock showed a clear bearish trend, with 38% of traders exhibiting bearish tendencies, which may exacerbate short-term volatility in the market for Eli Lilly's stock. The pharmaceutical industry is expanding U.S. production capacity, increasing policy risks.
    

Pfizer fell 0.56%, with a trading volume of $534 million. Based on recent important news:

1.  On September 22, Pfizer announced the acquisition of weight loss drug company Metsera for $7.3 billion, aiming to strengthen its position in the obesity drug market. This led to a roughly 2% increase in Pfizer's stock price in the morning, but it later fell back, indicating market skepticism about the long-term impact of the acquisition. Data source: multiple media reports.
    
2.  On September 22, analysts pointed out that Pfizer's weight loss drug development faced setbacks, and this acquisition was to compensate for gaps in its product line. The market is taking a wait-and-see approach regarding Pfizer's future product pipeline, affecting stock price volatility. Data source: Zhitong Finance.
    
3.  On September 24, Jefferies raised Pfizer's target price from $33 to $34, reflecting a cautiously optimistic view of Pfizer's potential post-acquisition. Data source: Jefferies. The competition in the obesity drug market is intensifying, and risks need to be monitored.
    

Merck fell 0.54%, with a trading volume of $490 million. Based on recent key news:

1.  On September 22, the U.S. Food and Drug Administration (FDA) approved a new subcutaneous injection formulation of Merck's blockbuster cancer therapy Keytruda. This marks a significant change in the administration method of the world's best-selling cancer immunotherapy, expected to enhance patient experience and treatment efficiency.
    
2.  On September 23, Merck signed a new memorandum of understanding with Siemens to accelerate artificial intelligence drug research and development. The two parties plan to expand their collaboration through new joint projects and deeper integration.
    
3.  On September 24, Merck announced the cancellation of its research operations in London due to challenges in the business environment, while AstraZeneca suspended its £200 million investment plan at its Cambridge research base. Industry trend: Drug price control policies are having an impact **Stocks Ranked Among the Top by Market Capitalization in the Industry**
    

Johnson & Johnson rose 0.02%, with a market capitalization of $425.3 billion and increased trading volume. Based on recent key news:

1.  On September 23, Johnson & Johnson announced it would withdraw its LINX gastroesophageal reflux management system from non-U.S. markets. This move was made for commercial reasons and did not report any safety or efficacy issues. This news may raise market concerns about the company's international business, leading to stock price fluctuations.
    
2.  On September 23, Guggenheim raised Johnson & Johnson's target stock price from $167 to $206. Analysts are optimistic about the company's future growth prospects, driving the stock price up.
    
3.  On September 22, Johnson & Johnson's PD-1 monoclonal antibody JNJ-67484703 did not achieve statistically significant results in its Phase II study for rheumatoid arthritis but demonstrated that the drug could effectively deplete PD-1 positive T cells. This news has implications for the company's prospects in the field of immunotherapy. Industry trend: ADC technology innovation, macro dynamics: economic data impact

### Related Stocks

- [IXHL.US - Incannex Healthcare](https://longbridge.com/en/quote/IXHL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股七雄變「雙熊」Meta 危危乎 亞馬遜創 20 年最長跌浪 關注股神會否再沽蘋果 | 美股七雄近期表現疲弱，部分已陷入熊市，亞馬遜創下 20 年來最長跌浪。市場對大型科技公司的資本開支及盈利能力產生質疑，尤其是亞馬遜的高額投資可能導致負自由現金流。分析指出，亞馬遜需展現投資回報以消除投資者憂慮。微軟雲業務預計在三年內超過 A | [Link](https://longbridge.com/en/news/276001219.md) |
| 通脹降溫、非農勁爆，美股能否止跌企穩？ | 美國 1 月 CPI 同比降至 2.4%，低於預期，核心 CPI 降至 2.5%，創 2021 年來最低，市場對美聯儲降息預期升溫。美股三大指數漲跌不一，納指小幅下跌但企穩於 24700 點上方。美債殖利率全線下跌，資金回流美債。投資者關注 | [Link](https://longbridge.com/en/news/275994601.md) |
| 金價曾插水挫 4% 銀價瀉近 12% 分析：美股大跌觸發演算法沽貨 | 金價一度下挫 4.1%，銀價跌 11.7%，因美股大跌引發算法交易賣盤。金價現回穩至 4981.5 美元，銀價 77.13 美元。分析認為，市場對人工智慧影響盈利的擔憂加劇拋售，追加保證金通知也加重了流動性壓力。儘管近期大跌，多家機構仍看好 | [Link](https://longbridge.com/en/news/275847502.md) |
| 美國通脹再回落 市場料最快 6 月減息 道指早段挫逾 300 點後倒升 | 美國通脹回落，1 月 CPI 按年升 2.4%，低於預期，推動美股反彈。道指一度跌 367 點後回升，最終上漲 61 點。市場對 6 月減息的預期上升至 66%。專家認為，通脹放緩有利於美股牛市，預計今年將減息兩次，最早在 6 月。 | [Link](https://longbridge.com/en/news/275920384.md) |
| 影響萬億資本的市場敍事爭奪：一邊是 “AI 顛覆一切”，一邊是 “AI 回報不夠” | 市場正陷入 “AI 顛覆一切” 與 “AI 回報不夠” 的雙重敍事博弈：前者引發對軟件等 “受害者” 的恐慌性拋售（估值腰斬），後者則加劇對資本開支回報的嚴厲審視。資金正加速流向非美市場，韓國 KOSPI 創五年最佳單週表現，非美基金流入  | [Link](https://longbridge.com/en/news/275990693.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.